Moderna Raises $2.6 Billion, Gets FDA Approval for mRNA-4157 and Gilead's New HIV Drug Bixlenvo Approved by FDA
Moderna's Large-Scale Capital Raise for Cancer Therapy Development and Vaccine Approval
Moderna (MRNA) has decided to issue $2.6 billion (approximately 34.6 billion USD) in convertible notes to attract R&D investment and repay debt. This fundraising followed the successful Phase 3 trial of its individualized neoantigen therapy (INT), intismeran autogene (mRNA-4157/V940), developed in collaboration with Merck, for melanoma. At the same time, the U.S. FDA approved Moderna's coronavirus vaccine, mNEXSPIKE, targeting the XFG variant. Despite a 10% stock price drop due to dilution concerns, this move is expected to serve as a financial cornerstone for Moderna's transformation into a diversified oncology-focused company, reducing reliance on a single product.
Gilead's FDA Approval of Bixlenvo, a Once-Daily Single-Tablet Regimen for HIV
Gilead Sciences (GILD) has received FDA approval for Bixlenvo, a once-daily single-tablet regimen (STR) for adult HIV-1 patients with suppressed virus. This drug combines the integrase strand transfer inhibitor (INSTI) bictegravir and the capsid inhibitor lenacapavir. It is the first once-daily pill for patients previously on complex regimens. Positive non-inferiority data from Phase 3 trials (ARTISTRY-1 and ARTISTRY-2) were published in The Lancet. This approval is expected to enhance treatment convenience for chronic HIV patients and strengthen Gilead's market leadership.
Generate:Biomedicines' Data Leak Before ERS and Stock Plunge
Generate:Biomedicines (GENB) experienced a stock plunge following the premature leak of clinical data for its anti-TSLP monoclonal antibody, golukibart (GB-0895). Three posters scheduled for presentation at the European Respiratory Society (ERS) in September were prematurely published on the ERS website, leaking Phase 1 results and Phase 3 design. This drug, a once-every-six-month treatment for asthma/COPD developed using a generative AI platform, was a key asset with high expectations. The incident highlights the importance of strict information management and disclosure compliance in safeguarding biotech company value and market trust.
ProFound Therapeutics' AI-Based Women's Health Drug Development Collaboration
ProFound Therapeutics has secured up to $350 million (approximately 466 billion KRW) in investment from the Bill & Melinda Gates Foundation for the development of a treatment for preeclampsia/eclampsia. The investment includes an upfront payment of $200 million and $150 million in milestone payments. ProFound plans to use its AI platform, ProFoundry, to analyze target proteins in the 'dark proteome'—previously overlooked areas in research. The Gates Foundation's investment is expected to provide a foundation for AI to contribute to research in women's health, a long-neglected field.
Moderna's $2.6 billion capital raise and the success of intismeran autogene (mRNA-4157) in Phase 3 trials for melanoma demonstrate the commercial viability of the mRNA platform in combination with Keytruda. This milestone could reshape the global melanoma treatment market, estimated at around $9 billion. Gilead's Bixlenvo offers an alternative for adult HIV patients who are not suitable for Biktarvy, a once-daily regimen, and is expected to widen the gap against competitors like GSK's Dovato, solidifying Gilead's dominant position in the $30 billion HIV treatment market. The premature data leak of Generate:Biomedicines' golukibart (GB-0895) has introduced short-term uncertainty and increased stock volatility in the anti-TSLP market, particularly in comparison to competitors like AstraZeneca and Amgen's Tezspire. ProFound Therapeutics' $350 million collaboration with the Gates Foundation is expected to contribute to the activation of the women's health biotech investment ecosystem by applying AI platforms to discover precision diagnostics and therapeutic targets in underdeveloped preeclampsia research.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/fda-covid-vaccines-moderna-generate-profound-bixlenvo/828929/